: Reasonable extent of lymphadenectomy in combination with perioperative reliable adjuvant countermeasure to prevent postoperative peritoneal metastasis, as a prophylactic therapy is indispensable to improve the results of surgical treatment of gastric cancer with serosal invasion. Further therapeutic modality should be improved to obtain life prolongation for patients with gastric cancer with disseminating peritoneal metastasis or for gastrectomized patients with postoperative peritoneal metastasis. We believe that intraoperative continuous hyperthermic peritoneal perfusion (CHPP) combined with intraabdominal chemotherpy would be a candidate for the most reliable adjuvant therapy as both prophylactic and therapeutic modalities against peritoneal metastasis from gastric cancer.
Introduction and Background
The results in the treatment of gastric cancer have improved in recent years. This improvement is primarily due to an increase in the number of patients treated for early gastric cancer, as well as to extensive lymph node dissection and positive accomplishment of concurrent resection of the surrounding organs that are involve & 2). However, in patients with advanced gastric cancer with serosal invasion, it is unclear whether extensive lymph node dissection significantly contributes to improvements in the results of treatment of gastric cancer, since the most likely pattern of recurrence is by means of peritoneal metastasis under these clinical conditions.
Scanning electron microscopy of a macroscopically normal peritoneum of patients with gastric cancer that had invaded the gastric serosa occasionally reveals that a few malignant cells have become lodged in the naked area of the submesothelial connective tissue, providing a picture of incipient peritoneal metastasis3 reported in 1980 that intraperitoneal hyperthermic treatment was feasible and effective using rats with implanted peritoneal cancers. We also reported an experimental study of the feasibility of CHPP for peritoneal carcinoma").
In a clinical setting, a successful outcome after intracavitary CHPP in one patient with pseudomyxoma peritinei was reported by Spratt12). We introduced this system as prophylactic') and therapeutic') modalities of peritoneal metastasis, and it is probably the first trial of CHPP in combination with an anticancer drug after gastric surgery .
After our reports, many surgeons have introduced CHPP not only for prophylactic therapy but also for the treatment of peritoneal metastasis with their own modification in the hyperthermic induction system. Results of CHPP as a prophylactic therapy of postoperative peritoneal metastasis have only beeb reported by us ;
CHPP as a Prophylactic
we summarize them, as follows.
Under general anesthesia in the operating room, after a gastrectomy, three silicon tubes were placed in the pelvic, and right and left subphrenic cavities, respectively. After closure of the abdominal wall, physiologic saline containing 10 g/ml mitomycin C, which had been heated to 48-50°C by passage through a tubular coil in a water bath, was infused into the peritoneal cavity through an intrapelvic tube attached to a pump at a rate of 200 ml/min for 50-60 min. The inflow and outflow temperatures were maintained at 44-45°C and 40-42°C, respectively. After the retained perfusate fluid had been drained spontaneously over the 24 hours that followed CHPP, the three tubes were removed.
Our results come from two trials ; one is a historical controlled study (1980) (1981) (1982) (1983) , and other is a randomized controlled study (1983) (1984) (1985) (1986) ) .
The subjects were all primary gastric cancer patients with macroscopic serosal invasion by the cancer and no macroscopic peritoneal metastasis. They all had had a curative gastrectomy in our clinic. ( 12) As shown in Tablel, in the historical controlled study, the postoperative 3-year survival rate of patients (74% ) in the treated group was significantly higher than the survival rate (53%) of those in the control group (p < 0.04) . In the randomized controlled study, the 5-year survival rate (64% ) of patients in the CHPP group was higher than that of patients in the control group (53% ) although there was no statistically significant difference (p = 0.2427) between the rates. Median survival time was prolonged to 77 months in the CHPP group compared with 66 months in the control group. Intraperitoneal hyperthermic chemoperfusion (CHPP) combined with aggressive surgery was performed in 48 gastric carcinoma patients with peritoneal carcinomatosis ; 18 gastric carcinoma patients with peritoneal carcinomatosis serving as controls were treated with surgery alone. The survival period was extended for the 48 patients who underwent surgery plus CHPP compared with the control patients (P = 0.00167) , as shown in Table 2 .
Of the 29 patients with peritoneal carcinomatosis in the upper abdominal cavity, the 21 patients treated with CHPP and surgery had survival periods superior to those of the 8 patients treated by surgery alone. The 5-year survival rate of the 18 CHPP patients with countable metastasis in the entire cavity was 41.6%, whereas the 50% survival duration of the control group was 110 days. Nineteen patients with numerous metastasis in the entire cavity died 
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J. Hyperthermic Oncol. 13 •k4•l : 1997 produced no antitumor effect on the deeply invasive microfoci. They proposed that to supplement this limited penetration, every effort must be made to surgically remove residual foci on the peritoneoserosal surface, as well as to extirpate the intraabdominal metastatic and/or infiltrated organs.
Based on these reports, CHPP combined with aggressive surgery is currently performed in many hospitals in Japan and in Western countries23) 24) as an adjuvant treatment in patients with advanced gastrointestinal and ovarian cancers.
Prospects in Future
The intraabdominal (i.p.) administration of cisplatin is one of the most effective therapies for peritoneal metastasis and cisplatin is widely used for not only CHPP but also conventional i.p. chemotherapy. However, the effect of fluid osmolarity on the therapeutic efficacy of i. Recently, Sugarbaker et al. 26 ) and Yonemura et al.27 ) have stressed the importance of a combined therapy of both cytoreductive surgery (peritonectomy procedures) and CHPP for peritoneal metastasis. They intended to remove all metastatic peritoneal lesions (peritonectomy) to the greatest extent, including gastrectomy. They reported that such intensive cytoreductive surgery combined with CHPP resulted in the markedly enhanced life prolongation. In the near future, peritonectomy combined with followed CHPP may become one of the most common aggressive treatment modalities for patients with gastric cancer with disseminating peritoneal metastasis.
